Skip to main content
. 2015 Sep 7;6(31):31344–31359. doi: 10.18632/oncotarget.5181

Figure 5. Comparison of immunotherapy of MUC1-expressing tumors using Ad5 [E1-, E2b-]-MUC1 vs. Tri-Ad5.

Figure 5

C57Bl/6 mice (n = 7/group) were inoculated with 106 MC-38-MUC1 cells subcutaneously in the left flank. Mice were administered 1010 VP (viral particle) of Ad5 [E1-, E2b-]-MUC1 or Tri-Ad5 (1:1:1 mixture of 1010 VP each of Ad5 [E1-, E2b-]-CEA, Ad5 [E1-, E2b-]-MUC1, and Ad5 [E1-, E2b-]-brachyury, 3 × 1010 VP total). A control group of mice received 3 × 1010 VP of Ad5 [E1-, E2b-]-null (no transgene). Tumor growth was monitored and volumes calculated. (*) indicates days when Ad5 [E1-, E2b-]-MUC1 treated mice had significantly smaller (p < 0.05) tumors than control mice and (^) indicates days when Tri-Ad5–treated mice had significantly smaller (p < 0.05) tumors than control mice. There was no significant difference (p > 0.1) between Ad5 [E1-, E2b-]-MUC1 vs. Tri-Ad5–treated mice at any time point. Error bars represent the SEM.